CircRNA Synthesis Market Size, Share & Trends Analysis Report By Product & Service (Reagents & Kits), By Application (Therapeutics Development), By End-use, By Region, And Segment Forecasts, 2025 - 2030

CircRNA Synthesis Market Size & Trends

The global circRNA synthesis market size was estimated at USD 184.8 million in 2024 and is projected to grow at a CAGR of 15.88% from 2025 to 2030. The circular RNA (circRNA) synthesis industry is experiencing significant growth, driven by several key factors. One primary driver is the inherent advantages of circular RNAs over linear mRNAs, including increased stability, enhanced protein expression, and reduced manufacturing costs. These benefits have attracted substantial investments and interest from biotechnology companies aiming to develop circRNA-based therapeutics and vaccines. For instance, in August 2022, Merck's significant investment in oRNA Therapeutics underscores the industry's confidence in circRNA's potential to revolutionize RNA-based medicine.

The COVID-19 pandemic has further accelerated the circRNA synthesis industry. The success of mRNA vaccines in combating SARS-CoV-2 highlighted the potential of RNA-based therapeutics, leading to increased research and development in this field. As per the recent studies published on National Institute of Health, the circRNA vaccines can protect animal models against various SARS-CoV-2 variants, showcasing improved efficacy and stability compared to traditional mRNA vaccines. This has spurred interest in developing next-generation vaccines and therapeutics utilizing circRNA technology.

Recent company developments also play a crucial role in driving the circRNA synthesis industry. Companies like Circio, Sail Biomedicines, and Orna Therapeutics have emerged, focusing on harnessing circRNA's therapeutic potential. These firms are exploring applications ranging from vaccines to gene and cell therapies, aiming to leverage circRNA's enhanced properties for various medical conditions. Such initiatives are expected to expand the applications of circRNA technology, further propelling market growth. For instance, in August 2024, Abogen Biosciences announced the development of a highly efficient RNA circularization cis-splicing system, referred to as the Cis-System, which enables the production of circular RNA.

Market Concentration & Characteristics

The market is witnessing a high degree of innovation, driven by the unique advantages of circRNAs, such as enhanced stability and prolonged protein expression. Recent advancements include the development of efficient circularization methods, optimization of internal ribosome entry sites to enhance translation, and the engineering of circRNAs for improved therapeutic efficacy. These innovations are paving the way for novel applications in vaccines, gene regulation, and cell therapies.

Collaboration and partnerships are pivotal in the circRNA synthesis industry, facilitating the sharing of knowledge and resources to accelerate development. Academic institutions and biotechnology companies are increasingly working together to explore circRNA applications. For instance, the development of circRNA promoting RNA (cpRNA) to enhance circRNA biogenesis exemplifies such collaborative efforts. These partnerships are instrumental in overcoming technical challenges and advancing the therapeutic potential of circRNAs.

As the market evolves, regulatory frameworks are adapting to ensure the safety and efficacy of circRNA-based therapeutics. Regulatory agencies are focusing on establishing guidelines for the manufacturing processes, quality control, and clinical evaluation of circRNA products. Compliance with these regulations is crucial for market approval and public acceptance. Companies are actively engaging with regulatory bodies to navigate the complex approval processes, ensuring that their products meet the required standards.

The market is experiencing significant product and service expansion. Companies are broadening their portfolios to include a range of circRNA-based solutions, from custom synthesis services to therapeutic candidates targeting various diseases. For example, GenScript offers custom circRNA synthesis services for sequences ranging from 100 bp to 4 Kb, catering to diverse research needs. This expansion reflects the growing recognition of circRNA's potential and the increasing demand for specialized products and services in this field.

The market is expanding globally, with significant activities in North America, Europe, and Asia-Pacific regions. Countries are investing in RNA research and infrastructure to establish themselves as leaders in this emerging field. For instance, Australia's RNA Blueprint outlines actions to support the development of the nation's RNA sector, indicating a strategic move towards regional expansion in RNA technologies, including circRNA. Such initiatives are fostering regional growth and collaboration, contributing to the global advancement of the circRNA synthesis industry.

Product & Services Insights

Reagents & kits dominated the market and accounted for a share of 47.29% in 2024. This is attributed to the Innovations in reagent formulations and kit designs, such as improved enzymatic reactions for RNA circularization and optimized buffers, are making these products more reliable and user-friendly. Additionally, the growing interest in circRNA-based therapeutics, particularly in oncology and vaccine development, is fueling demand for these tools. Companies like GenScript and New England Biolabs are actively expanding their reagent and kit offerings to cater to the rising demand, further driving growth in this circRNA synthesis industry segment.

The service segment is expected to register the highest CAGR over the forecast period. Service providers offer end-to-end solutions, including design assistance, circularization, purification, and quality control, enabling clients to accelerate their research and development timelines. The growing focus on circRNA-based drug discovery and vaccine development, particularly for applications in oncology and infectious diseases, further boosts the demand for synthesis services. Companies such as GenScript and Creative Biolabs are expanding their service portfolios to cater to the diverse and evolving needs of this burgeoning field, making tailored solutions a key market driver.

Application Insights

Therapeutics development accounted for the largest market revenue share of 63.81% in 2024. The development of therapeutics is a major driver for the circRNA synthesis industry, as circRNAs offer distinct advantages for medical applications, including enhanced stability, prolonged protein expression, and reduced immunogenicity compared to linear RNA. These properties make circRNAs particularly attractive for next-generation vaccines, oncology therapies, and rare genetic disease treatments. Companies like Orna Therapeutics and Circio are at the forefront of developing circRNA-based therapeutics, with ongoing efforts to address unmet clinical needs in areas such as mRNA vaccine improvements and targeted cancer therapies.

The drug discovery segment is expected to register a significant CAGR over the forecast period. The market is gaining traction in drug discovery due to the unique ability of circRNAs to modulate gene expression and protein production with high stability and efficiency. Their non-linear structure makes them resistant to exonucleases, enabling prolonged activity in cellular environments, which is crucial for high-throughput drug screening. Researchers are leveraging synthetic circRNAs to create robust in vitro models for studying disease mechanisms, testing potential drug candidates, and validating targets for therapeutic interventions, thereby driving circRNA synthesis industry growth.

End Use Insights

Pharmaceutical and biotechnology companies accounted for the largest market revenue share of 59.55% in 2024. CircRNAs offer distinct advantages, such as enhanced stability, prolonged protein expression, and reduced immunogenicity, making them ideal for applications in next-generation RNA-based therapeutics. Leading companies are investing heavily in research and partnerships to harness the technology for novel drug development, particularly in areas like oncology, rare genetic disorders, and infectious diseases. For instance, collaborations between circRNA-focused firms like Orna Therapeutics and larger pharmaceutical companies highlight the growing recognition of circRNAs' therapeutic value. Furthermore, the success of mRNA vaccines has shifted industry focus toward RNA technologies, positioning circRNAs as a transformative tool for pipeline diversification and addressing unmet clinical needs.

The academic and research institutes segment is expected to register a significant CAGR during the forecast period. The versatility of circRNAs in gene regulation, protein production, and therapeutic applications has fueled academic interest, resulting in an increase in research grants and funding for RNA-based projects. Institutes are actively exploring circRNA's roles in cancer, neurological disorders, and rare diseases, as well as their applications in developing vaccines and gene therapies. Furthermore, advancements in custom synthesis services and reagents have made circRNA research more accessible, enabling institutions to delve into novel therapeutic pathways. Collaborative efforts between academia and biotechnology companies are also accelerating translational research, driving innovation and fostering the adoption of circRNA technologies in early-stage drug discovery and development. This is expected to help this segment grow positively in this market.

Regional Insights

North America circRNA synthesis market dominated in 2024 and accounted for the market share of 45.12%. This growth can be attributed to the is driven by robust advancements in RNA-based therapeutics and the increasing prevalence of chronic diseases such as cancer and neurodegenerative disorders. Investments from biotech firms and government funding for RNA research, particularly in the U.S., are boosting innovation. The presence of key players and extensive clinical trials on circRNA therapeutics further propel circRNA synthesis industry growth in the region.

U.S. CircRNA Synthesis Market Trends

In the U.S., the market benefits from a well-established biotechnology sector and strong collaboration between academic institutions and industry players. The rising adoption of RNA-based therapies in personalized medicine and the support of FDA approvals for RNA therapies contribute significantly to the growth of circRNA synthesis technologies. Additionally, the growing demand for innovative treatments in oncology and rare diseases is a major driver.

Europe CircRNA Synthesis Market Trends

Europe's market is fueled by increased investments in biotechnology and genomic research, particularly in RNA technology. The European Union’s funding initiatives and collaborations between research institutions foster innovation in circRNA-based applications. Growing interest in advanced therapies for chronic diseases and rare genetic conditions accelerates demand for circRNA synthesis.

The UK’s circRNA synthesis market is driven by a robust biopharma ecosystem and strong government funding for RNA research. The presence of leading academic institutions focusing on RNA therapeutics and partnerships between startups and large pharmaceutical companies have significantly boosted research and commercialization efforts.

France’s focus on biopharmaceutical innovation and RNA research is driving the circRNA synthesis market. Government programs to enhance genomic research and the presence of advanced laboratories specializing in RNA-based therapies support market growth. Additionally, the country’s efforts to promote biotechnology startups provide opportunities for new developments in circRNA synthesis.

Germany’s leadership in biotechnology and pharmaceutical manufacturing is a key driver for the circRNA synthesis market. Strong funding for life sciences research, coupled with partnerships between academic institutions and biopharma companies, enhances the development of circRNA-based technologies. The growing adoption of RNA therapies in treating rare diseases and chronic conditions further boosts the circRNA synthesis industry.

Asia Pacific CircRNA Synthesis Market Trends

The Asia Pacific market for circRNA synthesis is expanding rapidly due to increased investments in biotechnology and healthcare infrastructure. Countries like China, Japan, and India are witnessing growing adoption of RNA-based therapeutics. Supportive government policies, collaborations between academic and industrial players, and rising demand for innovative treatments drive the market.

China's circRNA synthesis market is propelled by massive investments in biotechnology and a growing focus on RNA research. The government’s initiatives to promote genomics and precision medicine, combined with partnerships between domestic and international biopharma companies, are key drivers. Additionally, the increasing burden of chronic diseases creates demand for advanced RNA therapies.

In Japan, the market is driven by extensive research in RNA-based therapeutics and advancements in biopharma technology. Government funding for life sciences research and collaborations between academia and industry foster innovation. Japan’s aging population and the rising prevalence of chronic diseases further contribute to the adoption of circRNA-based treatments.

Middle East & Africa (MEA) CircRNA Synthesis Market Trends

The circRNA synthesis market in the Middle East is supported by the increasing focus on healthcare innovation and biotechnology research. Governments in the region, particularly in Saudi Arabia and the UAE, are investing heavily in genomics and advanced therapies. Rising demand for personalized medicine further boosts the adoption of circRNA synthesis technologies.

Saudi Arabia’s Vision 2030 initiative has significantly boosted investments in healthcare and biotechnology, driving the circRNA synthesis market. The establishment of advanced research facilities and partnerships with international biotech companies create opportunities for RNA-based therapies. The rising prevalence of genetic disorders and cancer fuels the demand for innovative treatments.

Kuwait’s focus on advancing healthcare infrastructure and promoting research in biotechnology supports the circRNA synthesis market. Investments in genomic research and collaborations with global biotech firms drive innovation. Additionally, the increasing burden of chronic diseases highlights the need for RNA-based therapies, further accelerating circRNA synthesis industry growth.

Key CircRNA Synthesis Company Insights

The market players operating in the circRNA synthesis market are adopting product approval and launches to increase the reach of their products in the market, improve their availability in diverse geographical areas, and enhance production/research activities. In addition, several market players are collaborating with each other to strengthen their market position. These strategies enable companies to increase their capabilities, expand their product portfolios, and improve their competencies.

Key companies are growing their market revenue by launching new products, collaborations and adopting various other strategies.

Recent Developments

• In April 2024, Circio announced the successful in vivo proof-of-concept for its circVec circular RNA platform technology, further strengthening its focus on gene therapy.

• In August 2024, Abogen Biosciences, has announced the development of a highly efficient RNA circularization cis-splicing system, referred to as the Cis-System, which enables the production of circular RNA.

• In October 2023, Circio and Neoregen Biotech announced the launch of a research collaboration focused on developing innovative circular RNA (circRNA) therapeutics using Circio's proprietary circVec technology. The collaboration will evaluate the effectiveness of Neoregen's NICT (Neoregen Intra-Cellular Delivery Technology) delivery system in improving cellular uptake and nuclear transfer of circVec vectors, comparing it to existing commercially available delivery technologies.

CircRNA Synthesis Market Report Scope

Global CircRNA Synthesis Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global circRNA synthesis market report based on product & services, application, end use and region.

• Product & Services Outlook (Revenue, USD Million; 2018 - 2030)

  • Reagents & Kits

  • Instruments

  • Services

• Application Outlook (Revenue, USD Million; 2018 - 2030)

  • Therapeutics Development

  • Drug Discovery

  • Other Applications

• End Use Outlook (Revenue, USD Million; 2018 - 2030)

  • Pharmaceutical & Biotechnology Companies

  • Academic & Research Institutes

  • Others

• Regional Outlook (Revenue, USD Million; 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • APAC

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait